Previous 10 | Next 10 |
BASEL, Switzerland, Sept. 21, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the closing of its previously announced...
BASEL, Switzerland, Sept. 16, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced upcoming investor events. ...
BASEL, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Paul R. Carter and Dr. Murray W. S...
- Acquisition of Innovative Small Molecule Platform Significantly Expands Rare Disease Pipeline - - VectivBio to Host R&D Day on September 21, 2021- BASEL, Switzerland, Aug. 31, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a cli...
Gainers: AFRM +32.4%. MNTS +11.8%. KPLT +10.5%. VECT +5.2%. OSUR +3.9%. Losers: TSP -10.6%. LTCH -6.8%. LTRPA -4.8%. ENVX -4.3%. RDHL -3.2%. For further details see: AFRM, MNTS, TSP and LTCH among after hours movers
BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions, today published ...
- Industry veterans bring decades of clinical, regulatory and commercial management expertise to VectivBio - - Nominees will stand for election at an Extraordinary General Meeting of shareholders on September 2, 2021 - BASEL, Switzerland, July 12, 2021 (GLOBE NEWSWIRE) -- Vect...
VectivBio Holding (VECT) announces that the U.S. FDA has granted orphan drug designation to apraglutide for the prevention of acute graft-versus-host disease ((aGVHD)).The FDA’s Orphan Drug Designation program is designed to advance the development of drugs and biologics intended to tr...
BASEL, Switzerland, June 24, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare c...
VectivBio Holding ([[VECT]] +1.9%) has dosed the first patient in its Phase 2 STARS Nutrition metabolic balance study evaluating apraglutide in colon-in-continuity ((CIC)) patients with short bowel syndrome with intestinal failure (SBS-IF). This Phase 2 trial is designed to evaluate the effic...
News, Short Squeeze, Breakout and More Instantly...
NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of card...
Simplicity Esports (WINR) is expected to report for quarter end 2024-02-29 BankUnited Inc. (BKU) is expected to report $0.62 for Q1 2024 Winmark Corporation (WINA) is expected to report for Q1 2024 SL Green Realty Corp (SLG) is expected to report $2.17 for Q1 2024 Union Bankshares...
VectivBio Holding AG (VECT) is expected to report for quarter end 2023-12-31